Ceribell

Ceribell is a neurotechnology company headquartered in Sunnyvale, California, focused on transforming the diagnosis and monitoring of seizures in acute care settings. The company has developed the Clarity EEG system, a rapid-deployment, point-of-care electroencephalography platform designed to bring real-time brain monitoring to the bedside without the need for specialized neurological expertise. At the core of the system is an AI-powered seizure detection algorithm that analyzes EEG data and delivers actionable insights within minutes of application. The platform is engineered for ease of use, enabling nurses and non-specialist clinicians to apply the device and interpret results quickly, dramatically reducing the time-to-diagnosis for non-convulsive seizures in ICU and emergency department environments.

Ceribell has established a meaningful commercial footprint across hospitals and health systems in the United States, positioning itself as a category leader in point-of-care neurodiagnostics. The company has raised over $100 million in a Series D funding round, reflecting strong investor confidence in both its clinical value proposition and commercial scalability. Non-convulsive seizures are notoriously difficult to detect without EEG monitoring and are estimated to occur in a significant proportion of critically ill patients, representing a large and underserved clinical need. Ceribell's progress in securing hospital partnerships and expanding clinical adoption signals growing recognition of rapid EEG monitoring as a standard of care in acute neurology.

Ceribell represents a significant step forward for the broader neurotechnology industry by demonstrating that sophisticated brain monitoring can be decentralized and made accessible outside of traditional neurology workflows. By combining hardware innovation with artificial intelligence, the company is bridging a critical gap between neurological expertise and frontline clinical care. This model has implications well beyond seizure detection, pointing toward a future in which continuous brain monitoring becomes a routine component of critical care medicine. As the neurodiagnostics space matures, Ceribell serves as a compelling example of how neurotech innovation can translate directly into improved patient outcomes and operational efficiency within the healthcare system.